Crossmark

Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation

Crossref DOI link: https://doi.org/10.1186/s12885-021-09121-8

Published Online: 2022-02-28

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ali, Mohamed Abdulwahab Mohamed

Harmsen, William Scott

Morsy, Khairy Hammam

Galal, Ghada Moustapha Kamal

Therneau, Terry M.

Roberts, Lewis Rowland
License Information

Text and Data Mining valid from 2022-02-28

Version of Record valid from 2022-02-28
More Information

Article History

Received: 15 January 2021

Accepted: 13 December 2021

First Online: 28 February 2022

Declarations

:

: This study was approved by the Institutional Review Board at Mayo Clinic Rochester USA. Informed consent was waived by the same committee due to the minimal risk nature of the study, which involved only chart review with no patient contact. All study subjects have approved Minnesota Research Authorization which has given us the permission to use their data for research purposes (written consent).All study related activities were performed in accordance with the Declaration of Helsinki.

: Not applicable.

: Dr. Roberts has served on advisory boards for AstraZeneca, Bayer, Eisai, Exact Sciences, Gilead Sciences, GRAIL, QED Therapeutics, and TAVEC and received research support from Ariad Pharmaceuticals, Bayer, Boston Scientific, Gilead Sciences, Glycotest, RedHill BioPharma, TARGET PharmaSolutions, and Fujifilm Medical Systems.All other authors have no competing/conflict of interest.

Document is current

Any future updates will be listed below